teplizumab 1 mg/mL

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Diabetes Mellitus, Type 1

Drug Information

Target Indication

Diabetes Mellitus, Type 1

Clinical Trial

Last updated: 12/12/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA1/8/2026

Teizeild

Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.

PRIME

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Asthma

Multiple Sclerosis

Asthma

Atrial Fibrillation

Embolism

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts